AVD-104 – Talk Bio

Actionable Insights Powered by AI

Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3

2 months ago talkbio0Tagged avacincaptad, AVD-104, Clinical trial failure, Clinical Trials, Dry AMD, Genus Aviceda, Geographic Atrophy, IZERVAY, pegol, Phase 3 prospects, Sialic Acid Binding Immunoglobulin-like Lectins

Aviceda; AVD-104; geographic atrophy; dry AMD; Phase 2b; SIGLEC trial; Izervay; avacincaptad pegol; clinical trial failure; Phase 3 prospects

Aviceda Secures $200M Series C Funding to Advance Ocular Drug AVD-104 into Late-Stage Trials

1 year ago talkbio0Tagged Age related macular degeneration, AVD-104, Genus Aviceda, Geographic Atrophy, late-stage clinical trials, Macular edema due to diabetes mellitus, Series C

Aviceda Therapeutics, AVD-104, Geographic Atrophy, Age-Related Macular Degeneration, Diabetic Macular Edema, Series C Funding, Late-Stage Clinical Trials